newly
diagnosed
treatment
information
research &
trials
publications webcasts find
support
seminars
& meetings
events doctors nurses about
IMF
helping
the IMF
 
      new & noteworthy     
  Share via del.icio.us Share via Digg

:
Help fund research and important educational programs.
more..

WHAT IS MYELOMA? : more..


PATIENT SERVICES : Reimbursement, legal, and other services.
more..

MYELOMA MANAGER™ : Capture your lab results and see how they change over time. more..

NEXPROFILER™ :
Treatment information tailored to your diagnosis.
more..

FREE MYELOMA INFO PACK : Order one today. more..

Read the MYELOMA MINUTE :
Our free e-mail newsletter.
more..

Read MYELOMA TODAY :
And get a free subscription.
more..

IMF Privacy Policy : The IMF is committed to protecting the security of your personal and health information. more..

 

      

Spring 2009 Volume 7, Issue 9
Fall 2008 Volume 7, Issue 8
Summer 2008 Volume 7, Issue 7
Spring 2008 Volume 7, Issue 6
Winter 2008 Volume 7, Issue 5
Fall 2007 Volume 7, Issue 4
Summer 2007 Volume 7, Issue 3
Spring 2007 Volume 7, Issue 2
Winter 2006 Volume 7, Issue 1
Fall 2006 Volume 6, Issue 10
Summer 2006 Volume 6, Issue 9
Spring 2006 Volume 6, Issue 8
Winter 2005/2006 Volume 6, Issue 7
Fall 2005 Volume 6, Issue 6
Summer 2005 Volume 6, Issue 5
Spring 2005 Volume 6, Issue 4
Winter 2004/2005 Volume 6, Issue 3
Spring 2004 Volume 5, Issue 10
Winter 2003/2004 Volume 5, Issue 9
October 2003 Volume 5, Issue 8
August 2003 Volume 5, Issue 7
June 2003 Volume 5, Issue 6
February 2003 Volume 5, Issue 5
Winter 2002/2003 Volume 5, Issue 4
October 2002 Volume 5, Issue 3
August 2002 Volume 5, Issue 2
Special Edition - June 2002 Volume 4, Issue 11
Winter 2001/2002 Volume 4, Issue 8
Spring 2009 Volume 7, Issue 9     PDF AVAILABLE
    
Myeloma Today Spring 2009 in PDF
Articles include:

* ASH 2008 Highlights for Patients
* 2009 IMF Research Grant Recipients Announced
* Korean Multiple Myeloma Working Party Comes Aboard IMWG
* Health Care Reform a Top Issue in 2009
* NLB members report from the XII International Myeloma Workshop
* MT in conversation with Prof. Roman Hajek, Chairman of the Czech Myeloma Group
Fall 2008 Volume 7, Issue 8     PDF AVAILABLE
    
Myeloma Today Fall 2008 in PDF
Articles include:

* The Role of Zolinza® in Multiple Myeloma
* Phase III Zolinza®/Velcade® Trial Opening Soon
* Serum Immunoglobulin Free Light Chain Assay in Myeloma
* Supportive Care: Steroid-Associated Side Effects in Patients with Myeloma
* Coping with Fear and Cancer Recurrence by John M. Ricco
* MT in conversation with IMF Board member Edith Peterson Mitchell, MD, FACP
Summer 2008 Volume 7, Issue 7     PDF AVAILABLE
    
Myeloma Today Summer 2008 in PDF
Articles include:

* A Conversation with IMF Scientific Advisory Board Member Dr. Sagar Lonial
* Update from ASCO; MT in conversation with Dr. S. Vincent Rajkumar
* Supportive Care: Gastrointestinal side effects associated with myeloma therapies
* MT in conversation with Prof. Dr. Hermann Einsele
* MT in conversation with new IMF Board member Loraine Boyle
Spring 2008 Volume 7, Issue 6     PDF AVAILABLE
    
Myeloma Today Spring 2008 in PDF
Articles include:

* A Conversation with IMF Scientific Advisory Board Member Dr. Alan Solomon
* Europe Update: Frontline Myeloma Therapy with Dr. Jesus San Miguel
* Curcumin in Multiple Myeloma with Dr. Bharat Aggarwal
* Clinical Trials Update with Dr. Keith Stewart
Winter 2008 Volume 7, Issue 5     PDF AVAILABLE
    
Myeloma Today Winter 2007 in PDF
Articles include:

* New Findings Reported at ASH
* Serum Free Light Chain Testing for Diagnosis and Monitoring; MT in Conversation with Dr. Sundar Jagannath
* Myelosuppression; MT in conversation with Kathy Lilleby, RN
Fall 2007 Volume 7, Issue 4     PDF AVAILABLE
    
Myeloma Today Fall 2007 in PDF
Articles include:
  • Patient & Caregiver Experience: Smoldering Battles: My Diagnosis with Smoldering Myeloma
  • Recommendations from the International Myeloma Working Group (IMWG): Prevention of blood clots associated with the use of thalidomide or lenalidomide
  • Peripheral Neuropathy; In Conversation with Ginger Love, RN
Summer 2007 Volume 7, Issue 3     PDF AVAILABLE
    
Myeloma Today Summer 2007 in PDF format
Articles include:
  • Mapatumumab: A New Cancer Therapy in Development, with Dr. Asher A. Chanan-Khan
  • US Myeloma Forum, with Michael S. Katz
  • Thromboembolic Events, with Deborah Doss, RN, OCN
Spring 2007 Volume 7, Issue 2     PDF AVAILABLE
    
Myeloma Today Spring 2007 in PDF format
Articles include:
  • The Role of VELCADE® plus DOXIL® in Multiple Myeloma; A Conversation with Dr. Robert Orlowski
  • Update on Revlimid® for the Treatment of Myeloma; A Conversation with Dr. S. Vincent Rajkumar
  • Health Care Becomes Key Issue in 110th Congress
Winter 2006 Volume 7, Issue 1     PDF AVAILABLE
    
Winter 2006 Myeloma Today in PDF
Articles include:
  • Report from ASH 2006
  • Updates from around the globe
  • Patient profile: African Explorer and Seeker, Dr. William Wheeler Jr.
Fall 2006 Volume 6, Issue 10     PDF AVAILABLE
    
Fall 2006 Myeloma Today in PDF
Articles include:
  • REVLIMID® Approved for Myeloma
  • Update from the Israeli Association of Myeloma Patients (AMEN)
  • Shifting Focus: My "New" Life with Multiple Myeloma
Summer 2006 Volume 6, Issue 9     PDF AVAILABLE
    
Summer 2006 Myeloma Today in PDF
Articles include:
  • The 2006 IMF Scientific Board Retreat
  • The 2006 Annual Meeting of the American Society of Clinical Oncology
  • The IMF Symposium at the ONS Annual Congress: Advancing Access to Multiple Myeloma Treatmen
Spring 2006 Volume 6, Issue 8     PDF AVAILABLE
    
Spring 2006 Myeloma Today in PDF
Articles include:
  • Focus on Myeloma and Plasma Cell Disorders; Conference Overview with Morton Coleman, MD
  • Update on the Role of Lenalidomide (Revlimid®) in Myeloma
  • The Role of Bortezomib in Previously Untreated Myelo
Winter 2005/2006 Volume 6, Issue 7     PDF AVAILABLE
    
IMF's Centers for Disease Control and Prevention (CDC) grant renewed for second year
With our CDC grant renewal for 2006, the IMF will reach out to additional communities, as well as strengthen the community relationships we formed in 2005.
    
Advocacy Update: Support for Cancer Priorities Short-Changed in President’s Budget
President Bush’s recent state-of-the-union speech set the stage for an annual federal spending proposal that threatens to further erode our nation’s long-standing commitment to advance the pace of medical research and drug access.
    
The Yin and Yang of Long-Term Survivorship
Philosophers in the Han dynasty (207 BCE to 9 AD) developed the concept of Yin and Yang, the idea that everything in the universe has its opposite. If this is so, where does cancer fit into this ancient method of understanding life?
    
American Society of Hematology - 47th Annual Meeting
Recap from the American Society of Hematology's 47th annual meeting held in Atlanta, Georgia on December 10–14, 2005. We have selected the major myeloma presentations for you to keep informed on the latest myeloma research that was presented.
    
Dear Reader
2006! Another new year, one filled with new opportunities, new partnerships, and renewed hope. As is customary it's also a time to look back on what we've achieved and this year I'm especially proud of what the IMF has accomplished.
    
The Stafford Family Funds Myeloma Research Grant
To date, the four WAMP swim-a-thon events have raised more than $40,000—enough to fund a grant in my dad's honor through the IMF research program. Our family plans to continue our efforts to help fund myeloma research in hopes for a cure for my
    
Flavia Hiatt Shares Her Story
On August 13, 2005, Flavia and her friends transformed the boardroom and mezzanine of Luxe Hotel Rodeo Drive in Beverly Hills into a fabulous fashion trunk show to benefit the IMF's myeloma research program. Shop For A Cure featured Flavia's own clot
    
2006 IMF Brian D. Novis Research Grant Awards
Grant Recipients Honored at IMF Scientific Advisors Meeting.
    
Combination Therapy with VELCADE plus Melphalan & Prednisone
At the 2005 annual meeting of the American Society of Hematology, Dr. Jesús F. San Miguel presented interim data on the ongoing GEM/PETHEMA study of VELCADE® (bortezomib) plus melphalan and prednisone (V-MP) in elderly, previous
    
Pain Management in Multiple Myeloma
Myeloma Today speaks with Daniel R. Kloster, MD
    
Transplant Nutrition
Myeloma Today speaks with Heather-Ann Younker, RD, CNSD
    
My Life With Myeloma
It's important to know that you can lead a good life—and a long one—even with myeloma.
    
Challenging Cancer with the Power of Painting
    
Board of Directors Profile: Matthew Robinson
This is a very exciting growth period for the Foundation. And it's enormously rewarding for me to apply my business experience of the last 20 years to helping the IMF accomplish its goals and objectives.
    
IMFers MAKE A DIFFERENCE!
2005 Member Fundraisers in Review
When the IMF started its member fundraising program several years ago, we had no idea how our members would respond. Would they be intimidated? After all, "fundraising" is a daunting word to some of us. Or would the opportunity of being pro
    
2005 Support Group Recap
As the IMF embarks on a new year, it serves well to look back at the accomplishments of 2005. It was an exciting year. Robin Tuohy, Kelly Cox, and I made visits to about a third of the myeloma support groups around the country. This was a very reward
    
Central Nebraska Myeloma Support Group
    
The IMF Returns to St. Petersburg, Russia
International Clinical Conference Promotes Myeloma Education
    
IMF Hotline Coordinators Answer Your Questions
My brother was just told he has a very rare form of myeloma called IgM. I can’t find anything on it and keep coming across discussions of something called “Waldenström’s macroglobulinemia.” Can you help?
Fall 2005 Volume 6, Issue 6     PDF AVAILABLE
    
Dear Reader
The IMF, along with researchers, physicians, patients, and industry leaders, is extremely excited as we prepare for the annual American Society of Hematology (ASH) meeting, this year being held in Atlanta, Georgia on December 10th through 13th. The I
    
Patient Perspectives: NUMBERS DON'T LIE, or do they?
In the business world we're often told that Figures Don't Lie, but that Liars Can Figure. While that may be true in some scandalous incidents of corporate wrongdoing, we who are cancer advocates also know that while medical statistics don't lie, that
    
IMF Around the Globe: Israeli Association of Myeloma Patients
The Israeli Association of Myeloma Patients, also known as AMEN, was founded to benefit the welfare of myeloma patients in Israel.
    
Sixth Annual Support Group Leader Retreat
The word "Retreat" is defined in various ways: (1) an act or process of withdrawing especially from what is difficult or dangerous, and also (2) a period of group withdrawal for meditation, study, and instruction under a director. Well, I would have
    
Making Clinical Trials More Patient-Friendly
All new cancer drugs must be proven safe and effective in clinical trials before they can be made available to patients. At the 2005 IMF Support Group Leader Retreat, IMFer and leader of the Manhattan and White Plains (New York) myeloma support group
    
Pathogenesis and Maintenance of Multiple Myeloma
Recent studies in my laboratory have identified a novel pathway promoting enhanced survival of chronic B cell malignancies. We demonstrated that B lymphocyte stimulator (BLyS), a member of the tumor necrosis factor family, was expressed in an autocri
    
MOZOBIL™, a potential new agent for Stem Cell Harvesting
Colony-stimulating factors such as G-CSF (filgrastim) induce the marrow to grow, while MOZOBIL is a new agent that aids in releasing stem cells into circulating blood where they can be collected by a process called apheresis.
    
Patient Experience: One Day at a Time...for 18 Years
The most powerful tool in a cancer patient's arsenal is the mind—when your body is beaten down physically, you can push your mind to keep you strong mentally while you face the challenges life has given you.
    
Education, Advocacy, and Awareness: Profile of Robin Tuohy
My family's journey through cancer began in September of 2000. My husband, Michael, and I were enjoying a family vacation with our children, Allison and Mikey, then ages 7 and 2. On one of the "kiddie" rides at Santa's Village, Michael experienced ex
    
IMF Hotline Coordinators Answer Your Questions
I have been diagnosed with a solitary plasmacytoma of the bone. What is it? And what is the likelihood that I will develop multiple myeloma?
    
The Multiple Myeloma ListServe
The Multiple Myeloma ListServ—affectionately called "The List" by its 1500 members—was founded by Michael Katz, an IMF Director, and June Brazil, a myeloma patient. At a time when the number of in-person myeloma support groups was nowhere
    
IMF Around the Globe: The Greater Montreal Multiple Myeloma Support Group
As The Greater Montreal Multiple Myeloma Support Group approaches its first anniversary, it is encouraging to review the progress that the group has made since our first meeting in November 2004.
    
Member Events: Gary C. Heuer, Jr. Memorial Golf Tournament
140 golfers started out the day’s activities with breakfast at Craigie Brae Golf Course in N. Chili, NY. Following the exciting 18-hole tournament, the event’s participants gathered for a chicken barbecue at Freeman Park in Mumford, NY.
    
Fundraising: Rocking in Rhode Island
Our mother, Carol Murray-Rossi, was diagnosed with multiple myeloma in 2003. But her personal struggle with this disease did not stop her from looking for ways to reach out and help others fighting myeloma.
    
Fundraising: Katie's Birthday Charity Bash
As Katie's birthday approached, she came to me with an idea of how she wanted to celebrate. In lieu of birthday gifts, Katie asked her friends to honor her grandmother by donating money to help cancer patients.
    
South Florida's Dynamic Duo: Cindy Feltzin and Vicki Anderson Ferraro
Every support group has a personality. Our group is a family. We want everyone who joins us to feel welcome, to feel safe, and to feel very hopeful.
    
IMF Board Member Interview with Benson and Carol Klein
Since being diagnosed, I have a different outlook. I used to worry about the little things. Now, I only think about the big picture.
    
Insights into New Myeloma Tx: Revlimid Study Tops List of Investigations that may Benefit Patients
Recently, the Myeloma Program at New York-Presbyterian Hospital/Weill Cornell Medical Center has generated a considerable amount of excitement by launching a study evaluating a combination regimen, known as BiRD, that includes the antibiotic Biaxin&r
    
Member Events: 4th Annual MMAMM Benefit Keeps Lee Grayson's Memory Alive
Lee, who never had children, or a hit song, or huge record deal, worried that his life would leave no mark on the planet. But those who knew him, and even those who never had the blessing of knowing him, feel his presence each year at MMAMM. "Ask any
Summer 2005 Volume 6, Issue 5     PDF AVAILABLE
    
Education, Advocacy, and Awareness:
Chicago IMF Patient & Family Seminar
The seminar inspired me so much that starting a myeloma support group in my area is now one of my top priorities. With newly found hope, education, and knowledge of the IMF's passion for finding a cure, we feel more in control of our situation.
    
Education, Advocacy, and Awareness:
Cancer, Civil Rights, and Political Placebos
When truth meets politics to collaborate for change, great things can happen for future generations.
    
Meet the IMF: Allan Weinstein Joins the IMF Board of Directors
I was diagnosed around September of 2002. I had a symptom but it wasn’t a typical myeloma symptom. I was treated for an infection, but the infection recurred, and my internist didn’t like that.
    
The IMF Welcomes David Siegel, MD, PhD
The IMF is pleased to announce that Dr. David Siegel has joined its Scientific Advisory Board.
    
IMF Hotline Coordinators Answer Your Questions
My father-in-law has myeloma and may be a candidate for a stem cell transplant. I am pregnant. Can my baby’s umbilical cord blood be used for his transplant?
    
The International Myeloma Foundation’s CDC Initiative
The IMF is thrilled to have received a grant from the CDC to help in their efforts to increase awareness among African Americans regarding hematologic malignancies.
    
Revlimid® (Lenalinomide): Where Do We Stand?
One way or another, it seems that the long wait for Revlimid may be nearing an end.
    
IMF Honors Kenneth C. Anderson, MD with 2005 Robert A. Kyle Lifetime Achievement Award
Dr. Anderson has done more for the field of multiple myeloma and related disorders than anyone else. He is most deserving of this Lifetime Achievement Award.
    
IMF Around the Globe
The IMF in Japan and Latin America
    
Myeloma stem Cells: Attacking the Disease at its Source
Our research focuses on studying the originating cell in myeloma (the myeloma stem cell) and developing treatments that target this cell and inhibit the production of new tumor cells.
    
Dear Reader
I have just returned from a very successful meeting in Stockholm, Sweden, where exciting updates on myeloma research and treatments were presented.
    
Patient Perspective: A Conversation with Tim and Donna Egan
    
Patient Perspective: Cancer Etiquette
The question most commonly asked of a patient is, “How are you?” There is inherently nothing wrong with such a question. But is it the standard “How are you?” we routinely ask when we aren’t really interested in the answer? Is it the mundane “How are
Spring 2005 Volume 6, Issue 4     PDF AVAILABLE
    
Program Highlights from the 10th International Workshop in Myeloma
    
IMFers Share Their Thoughts
    
Patient Perspective: Tracking My Numbers
My MGUS was found as a fluke during an annual physical in May, 1993. My total serum protein was slightly above the top of the normal range for that test and soon went back to normal. Otherwise, I still would not know that I have MGUS since I am still
    
Patient Perspective: My New First Birthday
    
Update on Lenalidomide (CC-5013; Revlimid®)
There has been intense research to develop a safer and more effective version of thalidomide. Lenalidomide (CC-5013; Revlimid®) is the first analog (close cousin) of thalidomide to enter clinical trials. It may prove to be more effective and safe
    
Meet New Members of the IMF Scientific Advisory Board
    
Supportive Care: Erectile Dysfunction - Current Treatment Options
Erectile dysfunction (ED) is a very common disorder that affects up to half the male population over the age of 40.
    
IMF Hotline Coordinators Answer Your Questions
What is the difference between the terms "myeloma" and "multiple myeloma?" "My grandmother died of multiple myeloma and now my dad has been diagnosed with this disease. Is myeloma hereditary?"
    
Supportive Care: Blood Tests
There are a number of factors that are likely to increase your comfort with a medical test. Susan J. Leclair, PhD, CLS (NCA)helps you understand why a test has been ordered for you, how it will be conducted, and what the reference ranges are.
    
Dallas Patient & Family Seminar
    
Community Goals Lead to Results
Are you more interested in myeloma research or cancer research? Is there a difference? What about other issues, like drug coverage and payments for PET scans? Can myeloma issues be separated from cancer issues in general?
    
IMF Receives Highest Four-Star Rating
    
Sorority Raises Funds for a Cure
During the summer of 2004, my father was diagnosed with multiple myeloma. Myeloma? I had never heard of this disease. And I was not alone.
    
Myeloma Foundation of Australia Inc.
    
2005 Brian D. Novis Research Grants
    
Did You Know: What Causes Hyperviscosity in Multiple Myeloma?
Viscosity is the property of fluid to resist flow. In myeloma patients, hyperviscosity (increased serum viscosity) results from increased levels of circulating serum immunoglobulins.
Winter 2004/2005 Volume 6, Issue 3
    
Advocacy Update: Federal Support for Cancer Issues in Decline
The science of cancer research holds unprecedented promise. Unfortunately, the issues of federal funding dominating the political agenda—for cancer research and drugs and treatments through Medicare—are not addressing this opportunity.
    
Message from the IMF President
2004 saw the realization of many of the IMF’s dreams.
    
ASH 2004: The Avalanche of Information Continues
The recent ASH meeting in San Diego included a huge amount of information relevant to myeloma.
    
New Developments in Multiple Myeloma
Dr. Morie Gertz of the Mayo Clinic brings up to date on new developments in treatment and supportive care.
    
The Expanding Role of Proteasome Inhibition in Multiple Myeloma
At the 2004 ASH meeting, data from a variety of proteasome inhibitor studies was discussed. Based on these, it seems safe to conclude that more patients with relapsed or refractory disease will benefit from such therapy than previously thought.
    
IMFer Profile: Andy Lebkuecher
Meet the New IMF Director of Support Groups
Like most people who find out one day that they or a loved one has myeloma, we’d never heard of it before. I said, “OK, I guess we need to learn about this.”...We attended an IMF Patient & Family Seminar and became very involved with the Foundation.
    
North Texas MM Support Group
Spring 2004 Volume 5, Issue 10
    
Los Angeles Area Support Group Salutes Leader
IMFers Pay Tribute To Janet Johnson
    
Message from IMF President
On behalf of the International Myeloma Foundation, I would like to thank you for your support and update you on our progress with the IMF’s research project, Bank On A Cure®.
    
Why Bank On A Cure®?
Every myeloma patient is unique. Treatment should be too.
    
Treating Multiple Myeloma: The Little Rock Approach
Peripheral blood stem cell (PBSC)-supported high-dose melphalan 200 mg/m2 is now considered standard therapy for patients with symptomatic or progressive myeloma. During the last five years, additional new agents effecting salvage rates of 30% - 50%
    
The Genetics of Multiple Myeloma
Extensive genetic lesions, both at the chromosome and gene levels, characterize malignant plasma cells. Although most patients present with a large number of malignant plasma cells at diagnosis (up to 1,000 billion malignant cells), chromosomal analy
    
Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the Proteasome
There are many difficult hurdles to overcome in the treatment of multiple myeloma, but one of the most important is a phenomenon called drug resistance.
    
Education Initiative
The International Myeloma Foundation (IMF) and Millennium Pharmaceuticals, Inc., of Cambridge, MA, the developer of VELCADE® (bortezomib) for Injection, are collaborating on a national medical education program designed for oncology nurses.
    
Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma
Atiprimod has a very interesting history, providing yet another example of a drug candidate that begins its story as a potential treatment for a wholly different disease indication.
    
Cancer Research and Medicare: Political Pork?
    
IMF Kicks Off 2004 Seminars with Florida Retreat
In talking with first-time participants as well as those who had attended IMF seminars previously, it is very evident that no matter how many of these wonderful weekends one has been to, there is always new, pertinent information available.
Winter 2003/2004 Volume 5, Issue 9     PDF AVAILABLE
    
2004 Research Grants Awarded to the Best
IMF Announces Key Worldwide Funding
Six of the world's most promising clinical investigators have been chosen to receive prestigious 2004 Brian D. Novis Research Grants from the International Myeloma Foundation (IMF) in order to further their research.
    
ASH 2003: An Avalanche of New Information
What does it all mean, and where do we go from here?
The huge number of presentations at the American Society of Hematology Meetings (ASH), December 4th – 9th 2003 in San Diego capped a truly momentous year for myeloma research and new drug development.
    
Message from IMF President
It’s that emotional time of year again, when we reflect back on the past year, sometimes with tears for what we’ve lost, sometimes with smiles for what we’ve achieved and for the sweet memories of people who have touched our lives.
    
Advocacy Update: Congress Adjourns
Thanks to the persistent work of Sen. Kay Bailey Hutchison (R-TX), the conferees to the Labor, Health and Human Services, and Education appropriations bill approved $500,000 to help support the IMF’s Bank On A Cure program.
    
News and Notes
    
Ask the Expert: What's New with the Use of VELCADETM in MM?
    
Who is the Unknown Patient?
    
Did You Know?
    
The Gift of Giving
October 2003 Volume 5, Issue 8     PDF AVAILABLE
    
Ask the Expert: The use of DOXIL® in multiple myeloma
An interview with Mohamad Hussein, M.D., Director of the Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio.
    
Myeloma at the Movies Lending Library
The IMF has set up a video lending library of a variety of presentations and question and answer sessions.
    
Saluting an Incredible Human Being:
Dr. Robert A. Kyle Receives Lifetime Achievement Award
Rochester, Minnesota is perhaps best known as the home of the Mayo Clinic. Most people to whom myeloma is not unknown also know that Rochester is home to Dr. Robert A. Kyle.
    
The IMF Visits Italy and France
Under the auspices of the IMF, IMF Scientific Advisors and distinguished Professors Mario Boccadoro and Jean-Luc Harousseau held the first ever IMF Patient & Family Seminars in their respective countries.
    
Myeloma Patients and Oncology Nurses to Benefit from IMF/Millennium Collaboration
The IMF and Millennium Pharmaceuticals have agreed to collaborate on a medical education initiative for oncology nurses nationally which will also benefit multiple myeloma patients in their care.
    
Veterans, Agent Orange, Multiple Myeloma, and VA Benefits
Veterans with MM who were exposed to Agent Orange (AO) are potentially eligible for a vast array of Department of Veterans Affairs (VA) benefits.
    
It’s Your Attitude... It’s Your Choice
Tom Bay, Ph.D. has asked audiences over and over again to answer the following questions: Whose life is it? Who’s responsible for it? What do you plan on doing about it? And last question… When?
    
Early studies indicate targeted radioactive drug may expand treatment options for myeloma
The studies involve the drug Quadramet, one of a new class of drugs that target radiation directly to bone and spare the rest of the body from exposure.
    
Letters
    
News and Notes
August 2003 Volume 5, Issue 7     PDF AVAILABLE
    
Dear Reader
    
News and Notes
    
Ask the Expert:
The Pathogenesis and Treatment of Multiple Myeloma Bone Disease
One of the most common symptoms that lead patients with multiple myeloma to first seek medical attention is bone pain. This pain is caused by the destruction of bone material induced by myeloma cells within the center of the bone.
    
IMF Support Group Leader Retreat
Forty support group leaders, co-leaders, representatives, and IMF staff participated in the fourth annual IMF Support Group Leader Retreat, held June 27-29 at Duke University in Durham, North Carolina. The retreat lived up to the expectations of reg
    
The Good, the Bad, and the Ugly of Cancer Public Policy
On the one hand, the state of the science of cancer research and patient care is the brightest it has ever been. On the other hand, the politics and policy impacting the cancer world seem to be moving in the exact opposite direction.
    
IMFer Profile: Terry Herman Shares Her Story
I had an average life. I've always thought I was extremely healthy. I exercised, took all the right vitamins and antioxidants, and ate all the right foods. I used to laugh because my husband Howie was always running to the doctor, always thinking tha
    
Scientific Advisor Profile: Meet New Members of the IMF Scientific Advisory Board
The International Myeloma Foundation is pleased to welcome Drs. Fonseca, Gibson, Shimizu, and Westin to its distinguished Board of Scientific Advisors.
    
She's Banking on Finding a Cure
IMF President Susie Novis was profiled in the Leader's and Success section of the Investor's Business Daily.
June 2003 Volume 5, Issue 6     PDF AVAILABLE
    
Profile Interview: Julian Adams, Ph.D.
The doctor who discovered VelcadeTM, talks to Myeloma Today UK.
    
FDA Approves VELCADE® for the Treatment of Relapsed and Refractory Multiple Myeloma
    
Dear Reader
For those not involved with Myeloma, the name Little Rock Arkansas evokes memories – good or bad – of President Clinton. For those of us who live in the Myeloma world, it means one thing: Dr. Bart Barlogie and his team at the center there.
    
Life Lessons from a Politician
In the rotunda of the Salt Lake City courthouse, a life-size bronze statue of Governor Scott Matheson comes striding out to meet you, its hand extended. It captures the energy Scott Matheson had in life. He was an extraordinary man.
    
Letters
At 53 years young, and at the pinnacle of my 25-year public relations career, I was struck by multiple myeloma....I took hold of myself and decided to go to any length to get healthy.
    
News & Notes
    
Myeloma Update
Overview of the IXth International Workshop on Multiple Myeloma, the International Prognostic Index, and Bank On A Curetm
    
Q&A: Get Your Questions Answered
February 2003 Volume 5, Issue 5     PDF AVAILABLE
    
Report from the Los Angeles IMF Patient & Family Interactive Seminar
    
Dear Reader
    
Ask the Expert: Staying Well During Chemotherapy
    
Indiana University Cancer Research Center Patient Dinner
    
A Complementary Approach: Dr. Shlomit Michaely, Ph.D., L.Ac.
    
Building Bridges: Boston Dedicates A New Bridge To Leonard P. Zakim
    
Letters
    
Ferreting for Facts in the Realm of Clinical Trials
Winter 2002/2003 Volume 5, Issue 4     PDF AVAILABLE
    
Dear Reader
The beginning of a new year is always exciting. It’s a fresh start a clean slate — anything is possible. More than ever, I hear myeloma experts and researchers say that they believe we are on the brink of making myeloma a chronic disease. Can cure be
    
Ribbon of Hope — Making a World of Difference
As The Unknown Patient and his Unknown spouse dragged their luggage onto the shuttle to Washington DC, there was much to celebrate. His battle with myeloma was approaching its thirteenth year and for reasons far from Unknown, he was still going stron
    
Did You Know?
Immunizations in myeloma patients
Vaccination can help reduce the risk of some infections in individuals with multiple myeloma.
    
Did You Know?
The Gift of Good Nutrition
Almost everyone values the gift of health. By making small dietary changes you can reap rewards all year round.
    
Ask the Expert: Thalidomide and the ImiDs
    
Research Progress Report: Dr. Ivan Van Riet
A striking feature of myeloma cells concerns their tendency to reside in the bone marrow compartment during the main course of the disease evolution. The microenvironment provides the appropriate signals for growth and survival of the tumor cells. Si
    
YOUR GIFTS AT WORK: 2003 Brian D. Novis Research Grant Awards
    
News & Notes
October 2002 Volume 5, Issue 3     PDF AVAILABLE
    
Legal Assistance for the Cancer Patient
    
Friends We Never Hoped to Meet
    
Dear Reader
    
Wamp Swim 2002
    
Ask the Expert:
Dr. Steve Schey Answers Your Questions
    
IMF Support Group Leaders’ Retreat 2002
    
Myeloma Center Spotlight: University of Arkansas for Medical Sciences
Comprehensive Molecular Management of Multiple Myeloma
    
Reflections on Myeloma – Past and Future Progress
    
Step-by-Step Nutrition Action Plans
August 2002 Volume 5, Issue 2     PDF AVAILABLE
    
IMF World Events
    
Dear Reader
    
Neuropathy and Monoclonal Gammopathy
    
Developing the Second Generation Myeloma Chip
    
PS-341: The Patient Experience
    
Multiple Musicians Against Multiple Myeloma
    
Advocacy Update: Connecting the Dots
Special Edition - June 2002 Volume 4, Issue 11     PDF AVAILABLE
    
OVAC 2002 Advocacy Day Senate Hearing: Oral Testimony of Susie Novis
    
The IMF Goes to Washington in the Special Edition of Myeloma Today
    
NCI Director Andrew von Eschenbach's Speech Highlights Patient-Family Seminar
    
Dear Reader
    
The IMF Goes to Washington
    
What Is the Bypass Budget?
    
Next Steps
    
Washington Comments
    
Full Text of Greg Brozeit's Cancer Landscape presentation at the June 2002 OVAC Advocacy Day.
Winter 2001/2002 Volume 4, Issue 8     PDF AVAILABLE
    
Excerpts from Acceptance Speeches at Cirque de la Vie
    
Thank You IMFers
It’s hard to believe that this year’s Ribbon of Hope-Making a World of Difference 11th Anniversary Gala has come and gone, raising close to $400,000!
      

We thank our web site sponsors

Amgen

Celgene Corporation

Proteolix

The Binding Site

We welcome our international partners:
Canada Czech Republic Europe Israel Japan Latin America
Copyright 2009. International Myeloma Foundation. All Rights Reserved.

International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
USA
phone: 800-452-2873 (US and Canada)
818-487-7455 (elsewhere)
fax: 818-487-7454
email: TheIMF@myeloma.org

International Myeloma Foundation Articles Master List International Myeloma Foundation Events Master List International Myeloma Foundation Support Groups Master List International Myeloma Foundation PDF Master List